drugset / Trial / NCT04062721

Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases

NCT04062721

Phase 1 Not yet recruiting 12 enrolled Assistance Publique - Hôpitaux de Paris
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to determine feasibility and tolerance of the human body to RFA associated with local immunomodulation carried out using a thermoreversible hydrogel combined with 2 immunomodulators, GMCSF and Mifamurtide. The main endpoint of the study is the feasibility, the frequency and the nature of per and post-operative adverse events of the in situ injection of an immunomodulatory hydrogel after radiofrequency of unresectable colorectal liver metastases. The secondary objective is one-year progression free survival rate.

Timeline

Start
2025-08
Primary completion
2028-11
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifamurtide Other / unclassified 8 ug/ml Other
Subject sargramostim Protein / enzyme biologic 25 ug/ml Other

Indications

No indication recorded.